- Kodiak Sciences (KOD, Financial) will present seven scientific presentations at ARVO 2025.
- Focus areas include novel treatments for ocular inflammatory diseases and Geographic Atrophy (GA).
- Early clinical data indicate that KSI-101 rapidly normalizes macular edema and improves vision.
Kodiak Sciences Inc. (KOD), a biopharmaceutical company based in Palo Alto, California, is set to make a significant impact at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting. The company will present seven scientific presentations between May 4-8, 2025, in Salt Lake City, highlighting their Antibody Biopolymer Conjugate (ABC) platform's versatility in addressing multifactorial ocular diseases.
Key highlights from Kodiak Sciences' research include promising advancements in treatments for ocular inflammatory diseases, particularly with their lead candidate, KSI-101. In the Phase 1b APEX study, KSI-101 has shown promising early clinical data, rapidly normalizing macular edema and improving vision in patients at all dosage levels. This candidate leverages Kodiak's bispecific protein platform to address inflammation-related vision problems and has demonstrated a positive safety profile.
In addition to ocular inflammation, Kodiak is advancing therapies for Geographic Atrophy (GA), a leading cause of vision loss. Their novel approach combines complement regulation with anti-VEGF and anti-IL-6 antibodies to simultaneously target multiple disease pathways, addressing both the prevention of wet AMD conversion and GA progression.
Another innovation from Kodiak is their ABCD platform, which enhances drug delivery by achieving a high drug-antibody ratio (DAR). This technology enables the embedding of therapeutic payloads, such as peptides and oligonucleotides, into a biopolymer backbone for targeted cellular delivery. Kodiak believes this could pave the way for next-generation targeted therapies for retinal and systemic diseases.
Kodiak Sciences' presentations at ARVO aim to emphasize their robust pipeline and showcase cutting-edge research in ocular disease treatment, offering potential breakthroughs for patients facing significant unmet medical needs.
